Changes in cytokine profile as a criterion for severity prediction of skin toxicity in cancer patients receiving epidermal growth factor receptor inhibitors

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

BACKGROUND: Globally, colorectal cancer is the third most diagnosed cancer with an increased incidence of 1.93 million cases in 2020 according to World Health Organization. Approximately one quarter of the initial manifestations of colorectal cancer are metastatic, and 40–50% of individuals with early-stage disease eventually develop metastatic colorectal cancer (mCRC). Targeted drugs, which include epidermal growth factor receptor inhibitors (EGFRi), are a frequent choice in the therapy of metastatic colorectal cancer. Clinical observations and in vivo studies have established a significant association between the administration of EGFRi drugs and skin inflammation, particularly acute in the first 3 months. However, the role of proinflammatory cytokines in the formation of severe skin lesions has not been definitively studied. Here we present clinical evidence of the involvement of a few cytokines in the formation of the pathologic cascade of reactions during EGFR blockade on keratinocyte membranes.

AIM: Evaluation of changes in cytokine profile parameters based on the MILLIPLEX Analyte MAP panel to identify predictors of the severity of unwanted skin toxicity associated with epidermal growth factor receptor inhibition.

MATERIALS AND METHODS: Blood serum samples from 81 patients aged 18–80 years who were taking EGFRi for oncologic disease and had adverse dermatologic reactions of severity 2 or more were analyzed. The data were analyzed using SPSS software and R 4.3.1 programming language and tidyverse, rstatix packages. Detected changes with p <0.05 were analyzed considering subgroup analysis on the basis of selected cutaneous toxicity severity degrees based on the criteria developed by the US National Cancer Institute NCI-CTC v. 4.

RESULTS: Blocking of EGF receptor inhibits the expression and release of vascular endothelial growth factor (VEGF), which is the main inducer of vascular proliferation, the consequence of which is inflammation of vascular endothelium of skin capillaries. Significant increase of IFN-γ and decrease of IFN-α2 level was found in patients with manifestations of skin toxicity of 2 and more severity degree. Also, a significant criterion of severity of the skin process was an increase in the level of TNF-α. At such dissociation there is induction of STING protein (interferon gene stimulator) and increase of TNF-β production that, in its turn, leads to increase of concentration of proinflammatory cytokines G-CSF, GM-CSF, IFN-α2, IFN-γ, IL-15, IL-17A, IL-1β, IL-3, IL-6, IL-8, IP-10, TNF-α, TGF-α, IL-9. This contributes not only to the maintenance of tissue inflammation, but also to the formation of a vicious circle leading to an increase in the severity of class-mediated inflammatory response against the background of further EGFRi administration.

CONCLUSION: Determination of predictors of severity of adverse dermatologic reactions is extremely important for predicting the development of severity and further personalized tactics for correction of adverse events.

全文:

受限制的访问

作者简介

Ekaterina Orlova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

编辑信件的主要联系方式.
Email: orlovaderm@yandex.ru
ORCID iD: 0000-0002-1684-8781
SPIN 代码: 6332-3970
Researcher ID: AAG-7087-2021

MD, Cand. Sci. (Medicine)

俄罗斯联邦, 4/1 Bolshaia Pirogovskaia street, 119435 Moscow

Marina Sekacheva

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: sekacheva_m_i@staff.sechenov.ru
ORCID iD: 0000-0003-0015-7094
SPIN 代码: 4801-3742

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, 4/1 Bolshaia Pirogovskaia street, 119435 Moscow

Marina Prokhorova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: examlpe@address.ru
ORCID iD: 0009-0004-8848-0674
俄罗斯联邦, 4/1 Bolshaia Pirogovskaia street, 119435 Moscow

Elena Zykova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: zykova.e.s@yandex.ru
ORCID iD: 0000-0003-4622-4934
SPIN 代码: 5085-0965

MD, Cand. Sci. (Medicine)

俄罗斯联邦, 4/1 Bolshaia Pirogovskaia street, 119435 Moscow

Anna Kuznetsova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: anyu.pushistaya@yandex.ru
ORCID iD: 0000-0002-9334-3816
俄罗斯联邦, 4/1 Bolshaia Pirogovskaia street, 119435 Moscow

Maxim Boot

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: ebut_mc@mail.ru
ORCID iD: 0009-0000-8468-2106
SPIN 代码: 1292-2693
俄罗斯联邦, 4/1 Bolshaia Pirogovskaia street, 119435 Moscow

Lyudmila Orlova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: examlpe@address.ru
ORCID iD: 0009-0005-8200-2716
SPIN 代码: 9525-2604
Scopus 作者 ID: 57210471902
Researcher ID: AAG-7087-2021.
俄罗斯联邦, 4/1 Bolshaia Pirogovskaia street, 119435 Moscow

参考

  1. Moriarity A, O’Sullivan J, Kennedy J, et al. Current targeted therapies in the treatment of advanced colorectal cancer: A review. Ther Adv Med Oncol. 2016;8(4):276–293. EDN: WPTXUP doi: 10.1177/1758834016646734
  2. National Institutes of Health, National Cancer Institute [Internet]. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0 [2017 Nov 27]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed: 15.04.2024.
  3. Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19(8):1079–1095. EDN: XZFWYZ doi: 10.1007/s00520-011-1197-6
  4. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6(10):803–812. doi: 10.1038/nrc1970
  5. Clabbers JM, Boers-Doets CB, Gelderblom H, et al. Xerosis and pruritus as major EGFRI-associated adverse events. Support Care Cancer. 2016;24(2):513–521. EDN: RMHMRS doi: 10.1007/s00520-015-2781-y
  6. Mittmann N, Seung SJ. Rash rates with EGFR inhibitors: Meta-analysis. Curr Oncol. 2011;18(2):e54–63. EDN: RJIKOB doi: 10.3747/co.v18i2.605
  7. Varlamova SE, Antimonik NY, Kozlova NM, et al. Domestic experience of prevention and treatment of skin toxicity in mCRPC patients receiving EGFR inhibitors, using Panitumumab as an example. RUSSCO project on development of recommendations for correction of dermatological reactions in patients receiving therapy with EGFRC inhibitors. Malignant Tumours. 2013;3(7):42–50. EDN: TBROAN
  8. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19):1272–1285. doi: 10.1056/NEJM199411103311906
  9. Woodworth CD, Michael E, Marker D, et al. Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol Cancer Ther. 2005;4(4):650–658. doi: 10.1158/1535-7163.MCT-04-0238
  10. Pastore S, Mascia F, Mariotti F, et al. ERK1/2 regulates epidermal chemokine expression and skin inflammation. J Immunol. 2005;174(8):5047–5056. doi: 10.4049/jimmunol.174.8.5047
  11. Chenyao W, Xin W, Manoj V, et al. EGFR-mediated tyrosine phosphorylation of STING determines its trafficking route and cellular innate immunity functions. EMBO J. 2020;39(22):e104106. doi: 10.15252/embj.2019104106
  12. Lacouture ME, Wainberg ZA, Patel AB, et al. Reducing skin toxicities from EGFR inhibitors with topical BRAF inhibitor. Therapy Cancer Discov. 2021;11(9):2158–2167. doi: 10.1158/2159-8290.CD-20-1847
  13. Koroleva IA, Bolotina LV, Gladkov OA, et al. Practical recommendations on drug treatment of dermatological reactions in patients receiving antitumour drug therapy. RUSSCO Practice Guidelines, Part 2. Malignant Tumours. 2023;12(3S2-2):101–122. EDN: BFQPZO doi: 10.18027/2224-5057-2022-12-3s2-101-122
  14. Bhupender SC, Keykavous P. Global cancer statistics 2022: The trends projection analysis. Chem Biol Letters. 2023;10(1):451.
  15. Pastore S, Lulli D, Girolomoni G. Epidermal growth factor receptor signalling in keratinocyte biology: Implications for skin toxicity of tyrosine kinase inhibitors. Arch Toxicol Springer Verlag. 2014;88(6):1189–1203. EDN: FYZYNW doi: 10.1007/s00204-014-1244-4
  16. Gerstein ES, Kushlinsky NE. Growth factors, their receptors and down-stream signaling proteins in human tumors: from experiment to clinical practice. Adv Mol Oncol. 2014;1(1):27–35. EDN: TBXUPL
  17. Polonskaya AS, Shatokhina EA, Kruglova LS. Dermatologic adverse events associated with epidermal growth factor receptor inhibitors: current concepts of interdisciplinary problem. Head Neck Tumors. 2021;11(4):97–109. EDN: VAVDFG doi: 10.17650/2222-1468-2021-11-4-97-109
  18. Orlova EV. Physiological functions of keratinocyte epidermal growth factor receptors and their role in the development of skin toxicity during targeted cancer therapy. Russ J Skin Venereal Dis. 2021;24(2):111–118. EDN: WLXWGU doi: 10.17816/dv63506
  19. Satoh TK, Mellett M, Meier-Schiesser B, et al. IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes. J Clin Invest. 2020;130(3):1417–1430. EDN: TYRSLX doi: 10.1172/JCI128678
  20. Litvyakov NV, Nechaev KA, Saprina TV, et al. CCR5 and rantes gene expression for interaction of peripheral blood mononuclear leukocytes in vitro and composite materials in patients with osteogenesis imperfecta. Genij Ortopedii. 2011;(3):117–121. EDN: OUHNGJ
  21. Yano S, Mentaverri R, Kanuparthi D, et al. Functional expression of β-chemokine receptors in osteoblasts: Role of regulated up on activation, normal T-cell expressed and secreted (RANTES) in osteoblasts and regulation of its secretion by osteoblasts and osteoclasts. Endocrinology. 2005;146(5):2324–2335. doi: 10.1210/en.2005-0065

补充文件

附件文件
动作
1. JATS XML
2. Fig. 1. MILLIPLEX MAP Human Cytokine/Chemokin panel results in the main group of patients (n=81).

下载 (327KB)
3. Fig. 2. Cytokine/chemokine scores in the study panel having a level of statistical significance of <0.05 in the metastatic colorectal cancer and lung cancer group.

下载 (919KB)

版权所有 © Eco-Vector, 2024



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86501 от 11.12.2023 г
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80653 от 15.03.2021 г
.